Inhibrx Biosciences (INBX) Total Liabilities (2023 - 2025)

Inhibrx Biosciences (INBX) has 3 years of Total Liabilities data on file, last reported at $138.5 million in Q4 2025.

• On a quarterly basis, Total Liabilities rose 193.51% year-over-year to $138.5 million in Q4 2025; TTM through Dec 2025 was $138.5 million, a 193.51% increase from a year earlier, with the FY2025 full-year figure at $138.5 million, up 193.51% from the prior year.
• Total Liabilities for Q4 2025 stood at $138.5 million, down from $140.6 million in the prior quarter.
• Over the last five years, Total Liabilities for INBX reached as high as $264.4 million in Q4 2023 and fell as low as $39.1 million in Q2 2024.
• Historically, Total Liabilities has averaged $120.7 million across 3 years, with a median of $139.6 million in 2025.
• Across the five-year window, Total Liabilities tumbled 82.15% in 2024 and surged 267.61% in 2025, its largest moves.
• Year by year, Total Liabilities stood at $264.4 million in 2023, then tumbled by 82.15% to $47.2 million in 2024, then jumped by 193.51% to $138.5 million in 2025.
• Per Business Quant data, the three most recent Total Liabilities figures were $138.5 million in Q4 2025, $140.6 million in Q3 2025, and $143.6 million in Q2 2025.